

Steven G Gray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5196196/publications.pdf>

Version: 2024-02-01

168
papers

5,424
citations

109137

35
h-index

91712

69
g-index

180
all docs

180
docs citations

180
times ranked

8256
citing authors

#	ARTICLE	IF	CITATIONS
1	The Human Histone Deacetylase Family. <i>Experimental Cell Research</i> , 2001, 262, 75-83.	1.2	507
2	Circular RNAs: Biogenesis, Function and Role in Human Diseases. <i>Frontiers in Molecular Biosciences</i> , 2017, 4, 38.	1.6	449
3	Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2005, 164, 10-21.	1.1	266
4	Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature. <i>PLoS ONE</i> , 2013, 8, e54193.	1.1	221
5	Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. <i>Oncogene</i> , 2003, 22, 6810-6818.	2.6	192
6	NF- κ B regulation: the nuclear response. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 631-643.	1.6	154
7	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. <i>Lung Cancer</i> , 2012, 76, 19-25.	0.9	153
8	Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells. <i>Cancers</i> , 2017, 9, 38.	1.7	143
9	Lung cancer stem cells: The root of resistance. <i>Cancer Letters</i> , 2016, 372, 147-156.	3.2	130
10	Role of histone and transcription factor acetylation in diabetes pathogenesis. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 416-433.	1.7	129
11	Functional Characterization of JMJD2A, a Histone Deacetylase- and Retinoblastoma-binding Protein. <i>Journal of Biological Chemistry</i> , 2005, 280, 28507-28518.	1.6	122
12	The RNA Methyltransferase NSUN2 and Its Potential Roles in Cancer. <i>Cells</i> , 2020, 9, 1758.	1.8	105
13	Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p16.1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 730-735.	1.8	97
14	Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis. <i>Epigenetics</i> , 2006, 1, 67-75.	1.3	94
15	Histone Acetylation / Deacetylation and Cancer: An Open and Shut Case?. <i>Current Molecular Medicine</i> , 2001, 1, 401-429.	0.6	87
16	Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2800-2821.	1.6	86
17	The emerging role of microRNAs in resistance to lung cancer treatments. <i>Cancer Treatment Reviews</i> , 2015, 41, 160-169.	3.4	83
18	Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p16. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 730-735.	1.8	76

#	ARTICLE	IF	CITATIONS
19	Receptor tyrosine kinases and their activation in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 446-461.	1.5	69
20	BB1608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. <i>Cancer Letters</i> , 2018, 428, 117-126.	3.2	69
21	Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. <i>Scientific Reports</i> , 2019, 9, 10739.	1.6	69
22	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	0.5	66
23	Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer. <i>Molecular Cancer</i> , 2015, 14, 45.	7.9	64
24	Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. <i>Oncotarget</i> , 2017, 8, 72544-72563.	0.8	60
25	Targeting oxidative stress in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1225-1245.	1.5	58
26	Altered expression of members of the IGF-axis in hepatoblastomas. <i>British Journal of Cancer</i> , 2000, 82, 1561-1567.	2.9	54
27	Effects of Cell Density and Trichostatin A on the Expression of HDAC1 and p57Kip2 in Hep 3B Cells. <i>Biochemical and Biophysical Research Communications</i> , 1998, 245, 423-427.	1.0	47
28	Epigenetics Underpinning the Regulation of the CXC (ELR+) Chemokines in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2011, 6, e14593.	1.1	44
29	Epigenetic treatment of neurological disease. <i>Epigenomics</i> , 2011, 3, 431-450.	1.0	43
30	Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. <i>Translational Lung Cancer Research</i> , 2020, 9, S100-S119.	1.3	43
31	Targeting histone deacetylases for the treatment of disease. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 826-852.	1.6	41
32	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. <i>Lung Cancer</i> , 2019, 131, 95-103.	0.9	40
33	Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. <i>European Journal of Cancer</i> , 2012, 48, 1096-1107.	1.3	39
34	IGF-I, IGF-II, and Insulin Stimulate Different Gene Expression Responses through Binding to the IGF-I Receptor. <i>Frontiers in Endocrinology</i> , 2013, 4, 98.	1.5	39
35	IGF-II Enhances Trichostatin A-Induced TGF β 1 and p21Waf1, Cip1, Sdi1 Expression in Hep3B Cells. <i>Experimental Cell Research</i> , 1999, 253, 618-628.	1.2	36
36	IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. <i>European Journal of Cancer</i> , 2011, 47, 1908-1918.	1.3	36

#	ARTICLE	IF	CITATIONS
37	The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer. <i>Cancers</i> , 2011, 3, 1426-1453.	1.7	35
38	Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. <i>Oncogenesis</i> , 2013, 2, e72-e72.	2.1	34
39	BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. <i>Journal of Pathology</i> , 2012, 227, 200-208.	2.1	33
40	IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 83-90.	0.9	33
41	Carcinogenesis in prostate cancer: The role of long non-coding RNAs. <i>Non-coding RNA Research</i> , 2018, 3, 29-38.	2.4	33
42	Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). <i>PLoS ONE</i> , 2013, 8, e70940.	1.1	33
43	Tissue context-activated telomerase in human epidermis correlates with little age-dependent telomere loss. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 297-308.	1.8	32
44	The SGBS cell strain as a model for the in vitro study of obesity and cancer. <i>Clinical and Translational Oncology</i> , 2012, 14, 774-782.	1.2	32
45	Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma.. <i>International Journal of Molecular Medicine</i> , 2000, 5, 33-41.	1.8	31
46	Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. <i>International Journal of Molecular Medicine</i> , 2012, 30, 1505-1511.	1.8	31
47	Comparative genomic hybridization reveals population-based genetic alterations in hepatoblastomas. <i>British Journal of Cancer</i> , 2000, 83, 1020-1025.	2.9	30
48	Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression. <i>PLoS ONE</i> , 2012, 7, e52753.	1.1	30
49	KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2016, 48, 1290-1296.	1.4	30
50	Methylation Changes in the Human IGF2 P3 Promoter Parallel IGF2 Expression in the Primary Tumor, Established Cell Line, and Xenograft of a Human Hepatoblastoma. <i>Experimental Cell Research</i> , 2001, 270, 88-95.	1.2	29
51	Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma. <i>JAMA Network Open</i> , 2022, 5, e221490.	2.8	29
52	The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1339-1356.	1.5	28
53	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays TM and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscope cohort. <i>Modern Pathology</i> , 2020, 33, 792-801.	2.9	28
54	The Insulin-like Growth Factors and Insulin-signalling Systems: An Appealing Target for Breast Cancer Therapy?. <i>Hormone and Metabolic Research</i> , 2003, 35, 857-871.	0.7	27

#	ARTICLE	IF	CITATIONS
55	Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 247-256.	1.4	27
56	Targeting Histone Deacetylases for the Treatment of Huntington's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 348-361.	1.9	26
57	Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2011, 3, 1550-1565.	1.7	26
58	Long noncoding RNAs in liver cancer: what we know in 2014. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1207-1218.	1.5	26
59	Targeting NF- κ B-mediated inflammatory pathways in cisplatin-resistant NSCLC. <i>Lung Cancer</i> , 2019, 135, 217-227.	0.9	25
60	Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. <i>Journal of Nanobiotechnology</i> , 2021, 19, 71.	4.2	24
61	Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. <i>European Journal of Cancer</i> , 2009, 45, 3087-3097.	1.3	23
62	Targeting Huntington's disease through histone deacetylases. <i>Clinical Epigenetics</i> , 2011, 2, 257-277.	1.8	23
63	Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer. <i>Cancer</i> , 2011, 117, 5121-5132.	2.0	23
64	Methylation, gene expression and the chromatin connection in cancer (review). <i>International Journal of Molecular Medicine</i> , 1999, 4, 333-50.	1.8	22
65	Endoplasmic reticulum stress "A double edged sword for Z alpha-1 antitrypsin deficiency hepatotoxicity. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 1403-1414.	1.2	21
66	Perspectives on epigenetic-based immune intervention for rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2013, 15, 207.	1.6	21
67	Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. <i>BMC Pulmonary Medicine</i> , 2021, 21, 148.	0.8	20
68	Human Histone Deacetylase 2, HDAC2 (Human RPD3), Is Localized to 6q21 by Radiation Hybrid Mapping. <i>Genomics</i> , 1998, 52, 245-246.	1.3	19
69	Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2009, 9, 84-107.	0.6	18
70	Sinapinic and protocatechuic acids found in rapeseed: isolation, characterisation and potential benefits for human health as functional food ingredients. <i>Irish Journal of Agricultural and Food Research</i> , 2017, 56, 104-119.	0.2	17
71	Induction of protein citrullination and auto-antibodies production in murine exposed to nickel nanomaterials. <i>Scientific Reports</i> , 2018, 8, 679.	1.6	17
72	In Arrayed Ranks: Array Technology in the Study of Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2009, 4, 411-425.	0.5	16

#	ARTICLE	IF	CITATIONS
73	Non-coding RNA repertoires in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2015, 90, 417-426.	0.9	16
74	Extraction and Quantification of Sinapinic Acid from Irish Rapeseed Meal and Assessment of Angiotensin-I Converting Enzyme (ACE-I) Inhibitory Activity. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 6886-6892.	2.4	16
75	SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18605.	1.6	16
76	Promoter-specific transcription of the IGF2 gene: a novel rapid, non-radioactive and highly sensitive protocol for mRNA analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 439, 803-807.	1.4	15
77	Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?. <i>Current Diabetes Reviews</i> , 2009, 5, 201-209.	0.6	15
78	IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 162.	1.3	15
79	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies. <i>Diagnostics</i> , 2018, 8, 60.	1.3	15
80	In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM). <i>International Journal of Molecular Sciences</i> , 2018, 19, 1297.	1.8	15
81	Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells. <i>Oncolmmunology</i> , 2018, 7, e1428156.	2.1	14
82	Insulin receptor substrates-5 and -6 are poor substrates for the insulin receptor. <i>Molecular Medicine Reports</i> , 2009, 3, 189-93.	1.1	13
83	Hemochromatosis: As a conformational disorder. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 2094-2097.	1.2	13
84	EGFR-AS1/HIF2A regulates the expression of FOXP3 to impact the cancer stemness of smoking-related non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985522.	1.4	13
85	Expression levels of insulin-like growth factor binding proteins and insulin receptor isoforms in hepatoblastomas. <i>Cancer Letters</i> , 2001, 162, 253-260.	3.2	12
86	Epigenetic-based immune intervention for rheumatic diseases. <i>Epigenomics</i> , 2014, 6, 253-271.	1.0	12
87	VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach. <i>Epigenomics</i> , 2015, 7, 897-910.	1.0	12
88	Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2017, 50, 1044-1052.	1.4	12
89	Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. <i>Translational Oncology</i> , 2021, 14, 101025.	1.7	12
90	Histone deacetylase 3 represses HTLV-1 tax transcription. <i>Oncology Reports</i> , 2006, 16, 581-5.	1.2	12

#	ARTICLE	IF	CITATIONS
91	Modulation of Splicing Events in Histone Deacetylase 3 by Various Extracellular and Signal Transduction Pathways. <i>Gene Expression</i> , 2003, 11, 13-21.	0.5	11
92	Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 605686.	1.8	11
93	Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. <i>International Journal of Oncology</i> , 2005, 26, 923.	1.4	10
94	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. <i>Frontiers in Endocrinology</i> , 2019, 10, 89.	1.5	10
95	Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. <i>Diagnostics</i> , 2019, 9, 13.	1.3	10
96	IGF-II AND IL-2 ACT SYNERGISTICALLY TO ALTER HDAC1 EXPRESSION FOLLOWING TREATMENTS WITH TRICHOSTATIN A. <i>Cytokine</i> , 2000, 12, 1104-1109.	1.4	9
97	Identifying cancer-related genes in nasopharyngeal carcinoma cell lines using DNA and mRNA expression profiling analyses. <i>International Journal of Oncology</i> , 2002, 21, 1197.	1.4	9
98	The therapeutic properties of resminostat for hepatocellular carcinoma. <i>Oncoscience</i> , 2018, 5, 196-208.	0.9	9
99	Histone deacetylase 3 represses HTLV-1 tax transcription. <i>Oncology Reports</i> , 0, , .	1.2	9
100	Novel Splicing of anIGF2Polymorphic Region in Human Adrenocortical Carcinomas. <i>Biochemical and Biophysical Research Communications</i> , 1997, 239, 878-883.	1.0	8
101	Epigenetic Methodologies for the Study of Celiac Disease. <i>Methods in Molecular Biology</i> , 2015, 1326, 131-158.	0.4	8
102	DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2007, 121, 992-998.	2.3	7
103	Transcriptional Regulation of IRS5/DOK4 Expression in Non-Small-Cell Lung Cancer Cells. <i>Clinical Lung Cancer</i> , 2008, 9, 367-374.	1.1	7
104	Reactive Oxygen Species and Reactive Nitrogen Species in Epigenetic Modifications. , 2014, , 437-455.		7
105	MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1773-1791.	1.3	7
106	Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model. <i>Scientific Reports</i> , 2016, 6, 18907.	1.6	6
107	Modeling RNA secondary structure. <i>Genome Biology</i> , 2001, 2, 1.	3.8	5
108	OUP accepted manuscript. <i>Clinical Chemistry</i> , 2022, , .	1.5	5

#	ARTICLE	IF	CITATIONS
109	Epigenetic Therapy in Lung Cancer and Mesothelioma. , 2015, , 189-213.		4
110	Mesothelioma Driver Genes, Ferroptosis, and Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 1318.	1.3	4
111	Pre-clinical models of small cell lung cancer and the validation of therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 187-204.	1.5	4
112	Correlation of integrated ERG/PTEN assessment with biochemical recurrence in prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100451.	0.7	4
113	Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1073-1079.	0.4	3
114	75P Inhibition and exploitation of aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker in cisplatin resistant NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, S87.	0.5	3
115	PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?. <i>Journal of Thoracic Oncology</i> , 2016, 11, e142-e144.	0.5	3
116	P1.05-021 circRNAs: Potential Novel Biomarkers for the Early Detection of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S626-S627.	0.5	3
117	Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases. <i>Cancers</i> , 2022, 14, 981.	1.7	3
118	hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro. <i>Cancers</i> , 2021, 13, 6383.	1.7	3
119	The Potential of Epigenetic Compounds in Treating Diabetes. , 2012, , 331-367.		2
120	Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2021, 16, 14-16.	0.5	2
121	Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach. <i>Methods in Molecular Biology</i> , 2021, 2279, 145-155.	0.4	2
122	Impact and correlation of mutational load (ML) and specific mutations (mts) assessed by limited targeted profiling (LTP) with PD-L1 tumour expression (exp) in resected non-small cell lung carcinoma (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11587-11587.	0.8	2
123	Gene Expression Profiling of Human Adipocyte Responses to Insulin and IGF-I Signalling. <i>The Open Diabetes Journal</i> , 2009, 2, 5-17.	0.4	2
124	Tumor proteomics. <i>Genome Biology</i> , 2001, 2, 1.	3.8	1
125	Altered expression of low affinity insulin-like growth factor binding protein related proteins in hepatoblastoma. <i>International Journal of Molecular Medicine</i> , 2002, 9, 645.	1.8	1
126	Epigenetic therapy for cisplatin resistance in non-small-cell lung cancer: the way forward?. <i>Lung Cancer Management</i> , 2013, 2, 1-4.	1.5	1

#	ARTICLE	IF	CITATIONS
127	Epigenetics of Cisplatin Resistance. , 2015, , 613-637.		1
128	70P Identification of a novel microRNA signature: Potential diagnostic biomarkers and predictors of cisplatin response?. Journal of Thoracic Oncology, 2016, 11, S85.	0.5	1
129	Epigenetic Regulation of Chemokine/Chemokine Receptor Expression. Methods in Molecular Biology, 2013, 1013, 185-201.	0.4	1
130	Squaring the circle: sponging microRNAs in gastric cancer. Translational Cancer Research, 2019, 8, S183-S187.	0.4	1
131	Finding mutations in your favorite gene. Genome Biology, 2001, 2, 1.	3.8	0
132	More mouse SNPs. Genome Biology, 2001, 2, 1.	3.8	0
133	Collecting splice variants. Genome Biology, 2001, 2, 1.	3.8	0
134	Prostate gene expression. Genome Biology, 2001, 2, 1.	3.8	0
135	Human-fly homologies. Genome Biology, 2001, 2, 1.	3.8	0
136	Asthma genetics. Genome Biology, 2001, 2, 1.	3.8	0
137	Transgenic and targeted mouse mutation database. Genome Biology, 2001, 2, 1.	3.8	0
138	COPEing with cytokines. Genome Biology, 2001, 2, 1.	3.8	0
139	Biovalley initiative. Trends in Genetics, 2001, 17, 132.	2.9	0
140	The Canadian biotech initiative. Trends in Genetics, 2001, 17, 251.	2.9	0
141	The Janus Serum Bank: forward thinking allows retrospective analysis. Trends in Genetics, 2001, 17, 316.	2.9	0
142	PartsList: a structural genomics resource. Trends in Genetics, 2001, 17, 316-317.	2.9	0
143	A new oncogenic FGF. Trends in Genetics, 2001, 17, 317.	2.9	0
144	Immunophenotyping leukemia by microarray. Trends in Genetics, 2001, 17, 442.	2.9	0

#	ARTICLE	IF	CITATIONS
145	Homology recognition: a FUGUE in a major key. Trends in Genetics, 2001, 17, 495.	2.9	0
146	SNP decisions. Trends in Genetics, 2001, 17, 495.	2.9	0
147	Neuroblastoma breakthrough. Trends in Genetics, 2001, 17, 565.	2.9	0
148	HACKing away at disease. Trends in Genetics, 2001, 17, 565.	2.9	0
149	Comparative bacteriology. Trends in Genetics, 2001, 17, 626.	2.9	0
150	Morning-after skin repair?. Trends in Genetics, 2001, 17, 626.	2.9	0
151	Picking your SNPs. Trends in Genetics, 2001, 17, 627.	2.9	0
152	MicroRNA in Oncogenesis. , 2012, , 89-110.		0
153	67P Investigation of the interaction between non-small cell lung cancer cells and immortalised normal bronchial epithelial cells. Journal of Thoracic Oncology, 2016, 11, S83-S84.	0.5	0
154	68P Inflammatory mediated mechanisms of cisplatin resistance in non-small cell lung cancer. Journal of Thoracic Oncology, 2016, 11, S84.	0.5	0
155	P2.01-031 CCL Chemokines May Play an Important Role in Cisplatin Resistance. Journal of Thoracic Oncology, 2017, 12, S803-S804.	0.5	0
156	P2.01-066 PD-L1 Tumor Expression and Its Effect on Overall Survival among Patients with Resected Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S827.	0.5	0
157	P2.03a-063 Small Molecule Cancer Stemness Inhibitor, BBI608, Restores Cisplatin Sensitivity in Resistant NSCLC. Journal of Thoracic Oncology, 2017, 12, S927-S928.	0.5	0
158	P2.03a-064 Inhibition and Exploitation of Aldehyde Dehydrogenase 1 as a Cancer Stem Cell Marker to Overcome Cisplatin Resistant NSCLC. Journal of Thoracic Oncology, 2017, 12, S928.	0.5	0
159	P3.01-042 Lung Cancer Cells Can Stimulate Functional and Genotypic Modifications in Normal Bronchial Epithelial Cells. Journal of Thoracic Oncology, 2017, 12, S1145.	0.5	0
160	P3.03-021 When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. Journal of Thoracic Oncology, 2017, 12, S1356-S1357.	0.5	0
161	MA02.02 A Novel 5-miR Signature Shows Promise as a Diagnostic Tool and as a Predictor of Cisplatin Response in NSCLC. Journal of Thoracic Oncology, 2017, 12, S348-S349.	0.5	0
162	P3.01-064 The Overexpression and Cleavage of SASH1 by Caspase-3 Stimulates Cell Death in Lung Cancer Cells. Journal of Thoracic Oncology, 2017, 12, S1158-S1159.	0.5	0

#	ARTICLE	IF	CITATIONS
163	We're Stressed Out: BETing on Oxidative Stress?. BioEssays, 2018, 40, e1800049.	1.2	0
164	The Potential of Epigenetic Compounds in Treating Diabetes. , 2018, , 489-547.		0
165	Epigenetic Targeting of Vascular Endothelial Growth Factor (VEGF) Receptors. , 2019, , 211-231.		0
166	Targeting Diabetes Pathogenesis via Histone Deacetylases. Targeted Protein Database, 0, , .	0.0	0
167	Epigenetic Targeting of Vascular Endothelial Growth Factor (VEGF) Receptors. , 2017, , 1-21.		0
168	The "eyes" have it? Intra- and inter-observer reproducibility of the PD-L1 companion diagnostic assay. Translational Cancer Research, 2017, 6, S1027-S1029.	0.4	0